BrightGene Bio-Medical Hits Day Low at CNY 36.05 Amid Price Pressure

BrightGene Bio-Medical Technology Co., Ltd. experienced a significant decline today, with the stock dropping by 5.61% and reaching an intraday low of CNY 36.05. This performance stands in contrast to the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, BrightGene's stock has decreased by 9.1%, while its performance over the last month shows a modest gain of 4.5%. However, the longer-term outlook reveals a stark decline, with a year-to-date drop of 25.25% and a staggering 65.05% decrease over the past year. In comparison, the China Shanghai Composite has shown a more stable performance, with a 3.56% increase over the past year. Financial metrics indicate that BrightGene is grappling with challenges, including a high debt-to-equity ratio and a return on equity of just 1.44%. The company has reported negative results for six consecutive quarters, with net profit declining by 65.94% in the first half of the year. Despite these difficulties, the stock maintains a high dividend yield of 0.04%.